Cargando…

Impact of Magnesium L-Lactate on Occurrence of Ventricular Arrhythmias in Patients with Implantable Cardioverter Defibrillators: A Randomized, Placebo-Controlled Trial

BACKGROUND: We evaluated the antiarrhythmic efficacy and quality of life (QoL) impact of oral magnesium Llactate on patients with an implantable cardioverter defibrillator (ICD). METHODS: This prospective, double-blind, placebo-controlled trial randomized 70 patients with an ICD to receive oral magn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, William L, Kluger, Jeffrey, Coleman, Craig I, White, C Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4768635/ https://www.ncbi.nlm.nih.gov/pubmed/27006710 http://dx.doi.org/10.2174/1874192401509010083

Ejemplares similares

Evolution of extravascular implantable cardioverter-defibrillator therapy for ventricular arrhythmias
por: Römers, Hans, et al.
Publicado: (2022)

Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator
por: Back, Steven H, et al.
Publicado: (2019)

Impact of Myocardial Bridge on Life‐Threatening Ventricular Arrhythmia in Patients With Implantable Cardioverter Defibrillator
por: Okada, Kozo, et al.
Publicado: (2020)

Ventricular arrhythmias among patients with implantable cardioverter‐defibrillator during the COVID‐19 pandemic
por: Malanchini, G., et al.
Publicado: (2021)

Diffuse myocardial fibrosis associates with incident ventricular arrhythmia in implantable cardioverter defibrillator recipients
por: Olausson, Eric, et al.
Publicado: (2023)

New atrial arrhythmia occurrence in single chamber implantable cardioverter defibrillator patients: A real‐world investigation
por: Patel, Divyang, et al.
Publicado: (2022)

Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and cardiovascular mortality in implantable cardioverter-defibrillator patients
por: Zhou, You, et al.
Publicado: (2019)

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
por: Noordman, Alwin B. P., et al.
Publicado: (2021)

Sex‐specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients
por: van der Lingen, Anne‐Lotte C.J., et al.
Publicado: (2021)

Implantable cardioverter defibrillator as a treatment for massive left ventricular fibroma-induced ventricular arrhythmia in a child
por: Choi, In Su, et al.
Publicado: (2021)

Performance of an automated external cardioverter defibrillator for inhospital ventricular malignant arrhythmia
por: Timerman, S, et al.
Publicado: (2003)

Comorbid Hypertension Reduces the Risk of Ventricular Arrhythmia in Chronic Heart Failure Patients with Implantable Cardioverter-Defibrillators
por: Huang, Hao, et al.
Publicado: (2022)

Ventricular tachycardia as presenting arrhythmia as a determinant of appropriate implantable cardioverter-defibrillator therapy in secondary prevention
por: Noordman, A B P, et al.
Publicado: (2023)

A sustained ventricular tachycardia overlooked by subcutaneous implantable cardioverter-defibrillator but recognized by co-implanted transvenous implantable cardioverter defibrillator
por: Goto, Kentaro, et al.
Publicado: (2020)

Association left ventricular lead and ventricular arrhythmias after upgrade to cardiac resynchronization therapy in patients with implantable cardioverter defibrillators
por: Kawamura, Mitsuharu, et al.
Publicado: (2019)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Main air pollutants and ventricular arrhythmias in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis
por: Yang, Hong-Jie, et al.
Publicado: (2017)

Genome-Wide Association of Implantable Cardioverter-Defibrillator Activation With Life-Threatening Arrhythmias
por: Murray, Sarah S., et al.
Publicado: (2012)

Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator
por: Burch, Ashley E., et al.
Publicado: (2019)

Implantable cardioverter-defibrillator shocks and nonsustained rapid ventricular rhythms
por: Witteveen, H., et al.
Publicado: (2022)

Implantable cardioverter-defibrillator shocks and nonsustained rapid ventricular rhythms
por: Witteveen, H., et al.
Publicado: (2022)

Primary Prevention of Fatal Ventricular Arrhythmias With Implantable Cardioverter-Defibrillator Therapy – An Analysis of Implications Based on MADIT II Criteria
por: Carrim, Zia I, et al.
Publicado: (2006)

An interesting implantable cardioverter defibrillator treatment for lethal ventricular arrhythmias caused by coronary artery spasm: A case report
por: Sun, Jie, et al.
Publicado: (2017)

Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
por: Zhou, You, et al.
Publicado: (2019)

Incidence of Ventricular Arrhythmias and 1‐Year Predictors of Mortality in Patients Treated With Implantable Cardioverter‐Defibrillator Undergoing Generator Replacement
por: Demarchi, Andrea, et al.
Publicado: (2021)

Appropriate Implantable Cardioverter-Defibrillator Therapy in Patients with Ventricular Arrhythmia of Unclear Cause in Secondary Prevention of Sudden Cardiac Death
por: Noordman, Alwin B. P., et al.
Publicado: (2023)

Successful Treatment of an Infant with Left Ventricular Noncompaction Presenting with Fatal Ventricular Arrhythmia Treated with Cardiac Resynchronization Therapy and an Implantable Cardioverter Defibrillator
por: Kimura, Masato, et al.
Publicado: (2018)

Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trial–Reduce Inappropriate Therapy (MADIT-RIT)
por: Aktas, Mehmet K., et al.
Publicado: (2020)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

Effects of COVID‐19 lockdown on arrhythmias in patients with implantable cardioverter‐defibrillators in southern Italy
por: Ducceschi, Valentino, et al.
Publicado: (2022)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Epicardial Cardioverter Defibrillator Implantation due to Post-Fontan Ventricular Tachycardia
por: Papakonstantinou, Nikolaos A, et al.
Publicado: (2020)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
por: Uslu, Abdulkadir, et al.
Publicado: (2018)

Remote Monitoring of Implantable Cardioverter Defibrillator
por: Reynolds, Dwight W, et al.
Publicado: (2006)

The Subcutaneous Implantable Cardioverter-Defibrillator: Not For All
por: Nair, Krishnakumar, et al.
Publicado: (2014)

Programming implantable cardioverter/defibrillators and outcomes
por: Horlbeck, Fritz W., et al.
Publicado: (2015)

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Subcutaneous implantable cardioverter‐defibrillator noise following left ventricular assist device implantation
por: Khetarpal, Banveet Kaur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_btdghle3k9n8bvbqapnia6ctfb